Metastatic Squamous Cell Carcinoma Clinical Trials

3 recruiting

Frequently Asked Questions

Common questions about Metastatic Squamous Cell Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 3

Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer

Oligometastatic Squamous Cell Carcinoma of the Head and Neck
European Organisation for Research and Treatment of Cancer - EORTC200 enrolled26 locationsNCT05815927
Recruiting
Phase 2

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

Head & Neck CancerMetastatic Squamous Cell CarcinomaOropharynx Squamous Cell Carcinoma+3 more
Wake Forest University Health Sciences32 enrolled1 locationNCT04858269
Recruiting
Phase 1

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

Head and Neck NeoplasmsNeoplasm MetastasisCarcinoma, Squamous Cell+3 more
University of Chicago36 enrolled1 locationNCT06912087
Recruiting
Phase 2

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Shanghai Miracogen Inc.116 enrolled1 locationNCT04868162
Recruiting
Phase 2

Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Groupe Oncologie Radiotherapie Tete et Cou70 enrolled1 locationNCT06640725
Recruiting
Phase 2

Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma

Squamous Cell Anal CarcinomaMetastatic Squamous Cell Carcinoma
Centre Hospitalier Universitaire de Besancon34 enrolled5 locationsNCT04894370
Recruiting
Phase 2

Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy

Metastatic Squamous Cell Carcinoma of the Vulva
The Netherlands Cancer Institute12 enrolled1 locationNCT04161664